Support for establishing the Therapy Acceleration Laboratory in Oxford to assess clinical trial samples (back translation)

治疗加速实验室将：a）使用专业的遗传学，免疫学，表型和病理学分析，从临床试验到加速治疗开发，包括与学术界，NHS和行业合作支持注册试验，为研究样本设定世界领先的质量和影响标准。B）通过使用最先进的技术和方法开发的机制研究，实现开辟生物学新领域的发现和应用。c）利用英国和国际生物医学领域的优势和能力，吸引最具创新性的临床试验，有可能迅速改变人类健康。已经有三个学术赞助的III期注册试验正在进行高级谈判，将于2021年10月至12月开始，这些试验将得到TAL的支持。受益者：将是患者，三个合作伙伴MRC单位，NHS，整个英国的其他学术单位，NHS和行业。

The Therapy Acceleration Laboratory would: a) Set world-leading standards in quality and impact to study samples, using specialist genetic, immunological, phenotypic and pathological assays, from clinical trials to accelerate therapy development, including supporting registrational trials in partnership with academics, the NHS and industry. b) Enable discovery and application that open new areas of biology with mechanistic studies developed using state-of-the-art technologies and methods.c) Utilise strengths and capability across the UK, and the international biomedical landscape, to attract the most innovative clinical trials with the potential to rapidly transform human health.Of note, there are already three academically sponsored Phase III registrational trials in advanced negotiation due to start between October and December 2021 that would be supported by the TAL. The beneficiaries: would be patients, the three partner MRC Units, the NHS, other academic units throughout the UK, the NHS and industry.